Krystal Biotech (NASDAQ:KRYS) Stock Price Expected to Rise, Citigroup Analyst Says

Krystal Biotech (NASDAQ:KRYS) had its target price boosted by investment analysts at Citigroup from $204.00 to $206.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Citigroup’s target price suggests a potential upside of 19.07% from the company’s previous close.

KRYS has been the subject of several other research reports. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Evercore ISI raised their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Buy” and a consensus target price of $197.00.

Krystal Biotech Price Performance

NASDAQ KRYS traded up $2.16 during trading hours on Tuesday, hitting $173.01. The company had a trading volume of 49,369 shares, compared to its average volume of 328,226. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The firm’s 50 day moving average is $182.28 and its 200 day moving average is $180.12. The company has a market capitalization of $4.97 billion, a price-to-earnings ratio of 47.13 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business’s revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.67) earnings per share. On average, equities analysts anticipate that Krystal Biotech will post 2.88 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 14.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. bought a new position in Krystal Biotech in the 2nd quarter worth $28,000. GAMMA Investing LLC raised its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Key Financial Inc purchased a new stake in Krystal Biotech in the second quarter worth about $28,000. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $53,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).